PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Keymeulen, B.* ; Vandemeulebroucke, E.* ; Ziegler, A.-G.* ; Mathieu, C.* ; Kaufman, L.* ; Hale, G.* ; Gorus, F.* ; Goldman, M.* ; Walter, M.C.* ; Candon, S.* ; Schandene, L.* ; Crenier, L.* ; de Block, C.* ; Seigneurin, J.M.* ; De Pauw, P.* ; Pierard, D.* ; Weets, I.* ; Rebello, P.* ; Bird, P.* ; Berrie, E.* ; Frewin, M.* ; Waldmann, H.* ; Bach, J.F.* ; Pipeleers, D.* ; Chatenoud, L.*

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

N. Engl. J. Med. 352, 2598-2608 (2005)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
BACKGROUND: Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3). METHODS: In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly assigned to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp-induced C-peptide release before and after the administration of glucagon. RESULTS: At 6, 12, and 18 months, residual beta-cell function was better maintained with ChAglyCD3 than with placebo. The insulin dose increased in the placebo group but not in the ChAglyCD3 group. This effect of ChAglyCD3 was most pronounced among patients with initial residual beta-cell function at or above the 50th percentile of the 80 patients. In this subgroup, the mean insulin dose at 18 months was 0.22 IU per kilogram of body weight per day with ChAglyCD3, as compared with 0.61 IU per kilogram with placebo (P<0.001). In this subgroup, 12 of 16 patients who received ChAglyCD3 (75 percent) received minimal doses of insulin (< or =0.25 IU per kilogram per day) as compared with none of the 21 patients who received placebo. Administration of ChAglyCD3 was associated with a moderate "flu-like" syndrome and transient symptoms of Epstein-Barr viral mononucleosis. CONCLUSIONS: Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.000
0.000
801
898
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Sprache englisch
Veröffentlichungsjahr 2005
HGF-Berichtsjahr 0
ISSN (print) / ISBN 0028-4793
e-ISSN 1533-4406
Zeitschrift New England Journal of Medicine, The / NEJM
Quellenangaben Band: 352, Heft: 25, Seiten: 2598-2608 Artikelnummer: , Supplement: ,
Verlag Massachusetts Medical Society (MMS)
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research (IDF)
PubMed ID 15972866
DOI 10.1056/NEJMoa043980
WOS ID 000229953700007
Erfassungsdatum 2005-06-23
[➜Korrektur melden]